Progressive multifocal leukoencephalopathy (PML) is typically associated with minimal inflammation; however, patients may develop an inflammatory response due to immune reconstitution (IRIS). The authors aimed to determine if characteristics and outcomes of PML are altered in those with IRIS. A retrospective records review was performed on 87 patients diagnosed with PML at Johns Hopkins, 27 of which had a syndrome consistent with IRIS. Gadolinium enhancement on MRI occurred in 44.4% of cases of PML-IRIS versus 5.1% in PML (p b 0.05), and thus had low diagnostic sensitivity and specificity. In HIV+ cases, CD4 counts were lower in those who later developed IRIS (mean 34.8 vs. 71.7, p b 0.05) and was predictive of the development of IRIS (p b 0.05). Improved prognosis was seen with higher cerebrospinal fluid (CSF) white blood cell counts and protein levels, but not for gadolinium enhancement and there were no differences in survival for PML versus PML-IRIS.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a rare viral infection of the central nervous system that is caused by the JC virus (Padgett et al., 1971) . PML usually develops in immunocompromised states, including human immunodeficiency virus (HIV), organ transplantation, hematological malignancies, and immunosuppressive therapies (Brooks and Walker, 1984) .
Nearly universally fatal in the setting of HIV infection in the past (Holman et al., 1991; Holman et al., 1998) , the advent of combination anti-retroviral therapy (cART) has increased the survival of those with PML to approximately 50% (Clifford et al., 1999; Antinori et al., 2001; Cinque et al., 2003) . Occasionally, despite cART, individuals with HIVrelated PML will continue to clinically decline despite restoration of their immune system -in which case a diagnosis of central nervous system (CNS) immune reconstitution inflammatory syndrome (IRIS) is considered.
CNS-IRIS is a clinical manifestation of rapid influx of immune cells into the central nervous system at the time of immune restoration (Rushing et al., 2008) . Associated risk factors are HIV-infection, preexisting opportunistic infection, being cART naïve, having a low nadir CD4 count prior to cART, and achieving a substantial decline in HIV viral load after instituting cART (Shelburne et al., 2005; Manabe et al., 2007; Dhasmana et al., 2008) . As much as 23% of HIV-infected patients with PML who recently started cART will develop PML-IRIS (Cinque et al., 2001; Falco et al., 2008) . PML-IRIS has also occurred in non-HIV cases of PML, such as in multiple sclerosis after removal of natalizumab by plasma exchange (Clifford et al., 2010) . PML-IRIS needs to be recognized early as this syndrome can result in death or permanent neurological disability (Tan et al., 2009) . The diagnosis of CNS-IRIS can be challenging as currently there are no established diagnostic criteria (Johnson and Nath, 2010) . In this study we characterized the differences between PML and PML-IRIS based on clinical, imaging, and laboratory data to elucidate specific predictors of conversion to IRIS and overall prognosis.
Methods

